Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FeDeriCa: SC Phesgo vs IV Pertuzumab+Trastuzumab in Early Breast Cancer
NCT03493854Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in HER2-positive breast cancer (2 arms), sponsored by Roche. Primary endpoint: Trough Serum Concentration of Pertuzumab During Cycle 7. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03493854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493854.